Strategic Blueprint LLC Sells 166 Shares of Moderna, Inc. (NASDAQ:MRNA)

Strategic Blueprint LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA) by 7.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,220 shares of the company’s stock after selling 166 shares during the quarter. Strategic Blueprint LLC’s holdings in Moderna were worth $221,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Redwood Wealth Management Group LLC increased its position in Moderna by 15.7% during the 4th quarter. Redwood Wealth Management Group LLC now owns 3,132 shares of the company’s stock valued at $311,000 after purchasing an additional 425 shares during the period. Bristlecone Advisors LLC increased its position in Moderna by 2.6% during the 4th quarter. Bristlecone Advisors LLC now owns 5,999 shares of the company’s stock valued at $597,000 after purchasing an additional 153 shares during the period. 180 Wealth Advisors LLC increased its position in Moderna by 1.9% during the 4th quarter. 180 Wealth Advisors LLC now owns 14,033 shares of the company’s stock valued at $1,396,000 after purchasing an additional 266 shares during the period. Arlington Trust Co LLC increased its position in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares during the period. Finally, Cubic Asset Management LLC increased its position in Moderna by 21.7% during the 4th quarter. Cubic Asset Management LLC now owns 3,925 shares of the company’s stock valued at $390,000 after purchasing an additional 700 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRNA. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Moderna in a research report on Thursday, March 28th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday. Finally, HSBC reaffirmed a “reduce” rating and issued a $86.00 target price (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $126.49.

Insider Activity

In other news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the completion of the sale, the president now owns 1,516,063 shares of the company’s stock, valued at approximately $157,518,945.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO James M. Mock sold 647 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the completion of the sale, the president now directly owns 1,516,063 shares of the company’s stock, valued at $157,518,945.70. The disclosure for this sale can be found here. Insiders sold 94,954 shares of company stock valued at $9,966,476 in the last quarter. 15.70% of the stock is currently owned by insiders.

Moderna Stock Performance

MRNA opened at $105.14 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company’s 50-day simple moving average is $99.71 and its two-hundred day simple moving average is $93.52. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $163.24.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.61 EPS. On average, research analysts forecast that Moderna, Inc. will post -7.48 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.